Evidence map›Paper›PMID 32971510›Full record

SynthesisEuropean journal of cancer (Oxford, England : 1990)2020

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies.

Kamal S Saini, Marco Tagliamento, Matteo Lambertini, Richard McNally, Marco Romano, Manuela Leone, Giuseppe Curigliano, Evandro de Azambuja

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European journal of cancer (Oxford, England : 1990), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 214 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
214citing papers in PubMed, 14 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

214 citing papers in PubMed, 14 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.Annals of oncology : official journal of the European Society for Medical Oncology · 2022
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

154 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kamal S SainiCovance Inc., Princeton, NJ, USA; East Suffolk and North Essex NHS Foundation Trust, Ipswich, UK.
Marco TagliamentoUniversity of Genova, Genova, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Matteo LambertiniUniversity of Genova, Genova, Italy; IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Richard McNallyCovance Inc., Princeton, NJ, USA.
Marco RomanoCovance Inc., Princeton, NJ, USA.
Manuela LeoneCovance Inc., Princeton, NJ, USA.
Giuseppe CuriglianoIstituto Europeo di Oncologia, IRCCS, Milan, Italy; University of Milano, Milan, Italy.
Evandro de AzambujaInstitut Jules Bordet, Brussels, Belgium; Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. Electronic address: evandro.azambuja@bordet.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with coronavirus disease 2019 (COVID-19) who have underlying malignancy have a higher mortality rate compared with those without cancer, although the magnitude of such excess risk is not clearly defined. We performed a systematic review and pooled analysis to provide precise estimates of the mortality rate among patients with both cancer and COVID-19.

methodsA systematic literature search involving peer-reviewed publications, preprints and conference proceedings up to July 16, 2020, was performed. The primary end-point was the case fatality rate (CFR), defined as the rate of death among patients with cancer and COVID-19. The CFR was assessed with a random effects model, which was used to derive a pooled CFR and its 95% confidence interval (CI).

resultsFifty-two studies, involving a total of 18,650 patients with both COVID-19 and cancer, were selected for the pooled analysis. A total of 4243 deaths were recorded in this population. The probability of death was 25.6% (95% CI: 22.0%-29.5%; I

conclusionsPatients with cancer who develop COVID-19 have high probability of mortality. Appropriate and aggressive preventive measures must be taken to reduce the risk of COVID-19 in patients with cancer and to optimally manage those who do contract the infection.

Indexed as

BetacoronavirusCoronavirus InfectionsCOVID-19HumansNeoplasmsPandemicsPneumonia, ViralPrognosisSARS-CoV-2Survival RateCancerCFRCOVID-19Death rateMalignancyMortalityPandemicSARS-CoV-2

Identifiers

PMID32971510
PMCPMC7467090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.